Modality
Peptide
MOA
CD47i
Target
CFTR
Pathway
NF-κB
Endometrial Ca
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
~Jul 2022
→ ~Oct 2023
Phase 2
Jan 2024
→ Oct 2025
Phase 2Current
NCT03173371
1,290 pts·Endometrial Ca
2024-01→2025-10·Terminated
1,290 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-185mo agoPh3 Readout· Endometrial Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2025-10-18 · 5mo ago
Endometrial Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03173371 | Phase 2/3 | Endometrial Ca | Terminated | 1290 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Datoglumide | AbbVie | Approved | CFTR | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Zenonesiran | GSK | Preclinical | DLL3 |